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The safety and efficacy of short course (5-day)
moxifloxacin vs. azithromycin in the treatment
of patients with acute exacerbation of chronic bronchitis
C. A. DEABATE*, C. P. MATHEW{, J. H. WARNER{ A. HEYD{ AND D. CHURCH{
*Medical Research Centers, New Orleans, Louisiana, {Westbank Research Centers, Gretna, Louisiana and {Bayer
Corporation, West Haven, Connecticut, U.S.A.
Chronic bronchitis is common among adults and infectious exacerbations contribute considerably to morbidity and
mortality. We aimed to compare the safety and ecacy of moxifloxacin to azithromycin for the treatment of
patients with acute exacerbations of chronic bronchitis (AECB) of suspected bacterial origin.
Between October 1998 and April 1999, 567 patients with AECB were enrolled at 37 centers across the United States
and Canada of which 280 (49%) had acute bacterial exacerbation of chronic bronchitis (i.e. pretherapy pathogen).
Patients were randomized to either oral moxifloxacin 400mg administered once daily for 5 days or azithromycin for 5
days (500mgqd61, then 250mgqd64). For the purpose of study blinding, all patients received encapsulated tablets.
The main outcome measure was clinical response at the test-of-cure visit (14–21 days post-therapy). Secondary
measures included bacteriologic response and a time-course of bacteriological eradication (one center only). Three
patient populations were analysed for ecacy: clinically-valid, microbiologically-valid (i.e. those with a pretherapy
pathogen), and intent-to-treat (i.e. received at least one dose of study drug).
For the ecacy-valid group, clinical response at the test-of-cure visit was 88% for patients in each treatment
group. In 237 microbiologically-valid patients, corresponding clinical resolution rates were 88% for 5-day
moxifloxacin vs. 86% for 5-day azithromycin. Bacteriological eradication rates at the end of therapy were 95% for
5-day moxifloxacin and 94% for the azithromycin group. Corresponding eradication rates at the test-of-cure visit
were 89% and 86%, respectively. Of note, eradication rates at test-of-cure for Haem. philos influenzae and H.
parainfluenzae for moxifloxacin were 97% and 88% compared to 83% and 62% respectively for azithromycin.
Among 567 intent-to-treat patients (283 moxifloxacin and 284 azithromycin), drug-related events were reported for
22% and 17%, respectively. Diarrhea and nausea were the most common drug-related events reported in each
treatment group.
Moxifloxacin 400mg once daily for 5 days was found to be clinically and bacteriologically equivalent to 5-day
azithromycin for the treatment of AECB of proven bacterial etiology. Given its excellent in-vitro activity, especially
against antibiotic-resistant respiratory pathogens, and its acceptable safety profile, moxifloxacin should be
considered an effective alternative therapy for patients with AECB of suspected bacterial origin.
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Acute exacerbation of chronic bronchitis (AECB) is
responsible for a significant amount of patient morbidity.
Approximately 50% of patients who experience acute
exacerbations will have at least two episodes per year
(1,2). Furthermore, approximately one in five patients with
AECB will require hospitalization for any given episode (3).Received 13 March 2000 and accepted 19 May 2000. Published
online 8 September 2000.
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Research Centers, 1020 Gravier Street, Suite 100, New Orleans,
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0954-6111/00/111029+09 $35?00/0Although the precipitating event leading to AECB is often
unknown, viral or bacterial infection is a common cause
(4). Haemophilus influenzae, Moraxella catarrhalis and
Streptococcus pneumoniae are responsible for the majority
of bacterial episodes (4,5). Although these pathogens may
be isolated during periods of quiescence, quantitative
cultures have demonstrated an increase in these pathogens
during an acute exacerbation (6,7). In patients experiencing
multiple exacerbations per year, not only are these three
core organisms likely to be causing infection, but Gram-
negative bacilli (e.g. Klebsiella pneumoniae, Pseudomonas
aeruginosa) become more probable. In any event, the
presence of pathogenic bacteria in the bronchial airways
can precipitate progressive airway deterioration and# 2000 HARCOURT PUBLISHERS LTD
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the major goals of therapy are to provide rapid clinical
resolution, eradicate the causative pathogens, and to
promptly return the patient’s respiratory function to their
pre-exacerbation baseline.
Over a decade ago, Anthonisen et al. reported that
antimicrobials appeared to be beneficial in patients with AECB
compared to those given placebo (8). His study also showed
that antimicrobials were most effective for patients categorized
as having type I symptoms (i.e. presence of dyspnea, increased
sputum volume, sputum purulence). A meta-analysis of
published randomized antimicrobial trials given for AECB
(1955–1994) has recently confirmed Anthonisen’s original
findings (9). During the last two decades, doxycycline, TMP/
SMX, and beta-lactams have been commonly prescribed for
patients experiencing an acute exacerbation (4).
In the outpatient setting, current managed care
practices have limited the physician’s ability to
determine whether an AECB is secondary to a bacterial
etiology (i.e. sputum cultures are infrequently obtained).
Accordingly, empiric antimicrobial therapy is often
prescribed for suspected acute bacterial exacerbations of
chronic bronchitis (ABECB). The selection of empirical
antimicrobial treatment must consider a number of
factors including the potential bacterial etiologies, the
likelihood of drug-resistant organisms, the severity of the
infection, underlying co-morbidities, and the need for
hospitalization.
A recent challenge in the treatment of ABECB is the
emergence of resistance to traditional antibiotics amongst
the commonly isolated respiratory pathogens. The overall
prevalence of beta-lactamase production has been reported
for approximately 35% of H. influenzae isolates and490%
of M. catarrhalis isolates (10,11). Other recent surveillance
studies have reported that approximately 25–45% of S.
pneumoniae isolates are penicillin-resistant, of which high
level resistance accounts for almost one-third of all isolates
(10,12–14). Although penicillin resistance is of interest, it is
more significantly a marker for beta-lactam and macrolide
resistance; however, little cross-resistance has been noted
among the fluoroquinolones (15). Based on these findings,
new alternative therapies that are highly effective against
the key respiratory pathogens are needed to combat the
rising level of antimicrobial resistance, especially multiple
antibiotic-resistant S. pneumoniae.
The main purpose of the current trial was to compare the
ecacy and safety of a 5-day moxifloxacin vs. 5-day
azithromycin regimen in the treatment of outpatients with
AECB of suspected bacterial origin. A secondary objective
of the study was to compare the rate of bacteriologic
eradication between moxifloxacin and azithromycin.
Methods
STUDY DESIGN AND ANTIMICROBIAL
THERAPY
This was a prospective, double-blind, randomized,
multicenter trial designed to compare moxifloxacin toazithromycin in the treatment of patients with AECB.
Patients were randomized in blinded fashion at the first visit
in a 1:1 ratio to moxifloxacin 400mg once daily for 5 days
(Bayer Pharmaceutical, West Haven, CT, U.S.A.) or
azithromycin 500mg once daily for the first day (loading
dose), followed by 250mg once daily for a total of 4 days
(Pfizer Inc, New York, NY, U.S.A.) based on a randomiza-
tion code that was computer-generated by Bayer Corpora-
tion. Following random assignment to treatment, all
patients took two encapsulated tablets once daily on day
1 (patients randomized to moxifloxacin received one active
and one placebo tablet), followed by one encapsulated
tablet on days 2–5. Study drug was taken at approximately
the same time of day with 120ml of water, with or without
food. At the end of therapy, each patient was questioned
regarding the number of capsules taken during the
treatment period and a pill count performed in order to
document patient compliance.
STUDY POPULATION
Patients eligible for inclusion in the study were outpatients
at least 18 years old with a suspected ABECB. Underlying
chronic bronchitis was defined as the daily production of
sputum on most days for at least 3 consecutive months and
for more than 2 consecutive years. Patients with a diagnosis
of chronic obstructive pulmonary disease (COPD) were
also eligible for enrollment. Patients with mild to moderate
respiratory exacerbations were entered into the study and
categorized as types I, II or III [as defined by Anthonisen et
al. (8) and the American Thoracic Society (16)]. The acute
nature of the infection was documented by recent increases
of bronchopulmonary symptoms and laboratory evidence
of an acute lower respiratory tract bacterial infection. All
study participants were required to have had increased
purulent/mucopurulent sputum and at least one of the
following: increased cough, increased dyspnea, increase of
sputum volume, or presence of fever (oral temperature
4388C).
Patients were excluded for the following reasons: allergy
or severe adverse reactions to carboxyquinolone derivatives
or azalide/macrolide derivatives; previous history of fluor-
oquinolone-related tendinopathy; unable to take oral
medication; pregnancy or lactating; chest X-ray suggestive
of a new pneumonia; recent diagnosis or unresolved lung or
chest cavity malignancy; neutrophil count 41000mm73,
CD4 count 4200mm73 or other evidence of significant
immunosuppression; evidence of significant liver impair-
ment (AST, ALT or total bilirubin more than three times
upper limit of normal); renal insuciency requiring dialysis;
history of QTc prolongation; or a need for a concomitant
antibacterial agent with a spectrum of activity similar to the
study drugs. Prospective patients were also excluded if they
received drugs known to affect QT interval (e.g. amiodar-
one, sotalol, terfenadine); or received previous therapy with
a systemic antibiotic for more than 24 h prior to enrollment.
Adjunctive medications including bronchodilators, muco-
lytics, or expectorants were permitted according to usual
physician practice in each treatment group. The study was
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and all patients provided written informed consent prior to
enrollment.
CLINICAL BACTERIOLOGIC AND SAFETY
ASSESSMENTS AND DEFINITIONS
Clinical response
A clinical response was determined at both the end of
therapy (0–6 days post-therapy) and at the test-of-cure (14–
21 days post-therapy) evaluations. Clinical response was
based on serial examinations of the patient using the
following parameters: objective signs of auscultatory
findings (rales, rhonchi, wheezing, breath sounds); prolon-
gation of expiratory phase; presence of fever 4388C;
presence of WBC412 000 cellsmm73; subjective symptoms
of chest pain or discomfort; change in cough frequency and
severity; sputum characteristics (thickness and volume);
dyspnea. At the end of therapy, clinical response was
graded as clinical cure [disappearance of acute signs and
symptoms related to the infection (complete return to a
stable pre-exacerbation condition) or sucient improve-
ment such that additional or alternative antimicrobial
therapy was not required], clinical failure (insucient
lessening of the signs and symptoms of infection such that
additional or alternative antimicrobial therapy was re-
quired), or indeterminate (clinical assessment was not
possible to determine for any reason). The clinical response
at the test-of-cure visit was reported as: continued clinical
cure (disappearance of acute signs and symptoms of
infection or continued improvement where additional or
alternative antimicrobial therapy was not required), clinical
recurrence (reappearance of signs and symptoms of AECB
considered related to a bacterial process such that
reinstitution of antimicrobial therapy was required), or
indeterminate (patients in whom a clinical assessment was
not possible to determine). In addition, clinical failure at the
test-of cure visit was considered in patients with either an
end of therapy evaluation of failure or a follow-up
evaluation of recurrence.
Bacteriologic Response
Bacteriologic evaluation (Gram stain and sputum culture)
was performed pretherapy, during therapy (days 1–5), at
the end of therapy visit (post-therapy days 0–6) and at the
test-of-cure visit (post-therapy days 14–21). For all isolated
organisms, E-test susceptibility testing were performed for
azithromycin according to NCCLS guidelines; an MIC
42mcgml71 was considered a borderline result for
moxifloxacin (17,18). Haemophilus spp. and M. catarrhalis
also were tested for beta-lactamase production. S. pneumo-
niae was tested for penicillin susceptibility, either by
oxacillin disk or by penicillin E-test strip.
During therapy (treatment days 1–5), patients at one
center were asked to return to the investigator’s clinic on a
daily basis in order to provide a sputum specimen forculture. For patients unable to return on a daily basis,
instructions were provided on the proper production and
storage of sputum specimens. Sputum specimens collected
on this basis were stored under conditions of refrigeration
for not longer than 24 h prior to culture and Gram stain.
Culture and Gram-stain results were recorded on a daily
basis for each specimen along with the date of eradication
of the causative organism(s). The date of eradication was
defined as the earliest date on which there were two
successive negative cultures.
At the end of therapy the bacteriological responses were
graded as eradication, presumed eradication (if no material
was available due to a clinical success), persistence,
presumed persistence (no material was available in a
patient considered a clinical failure) or indeterminate (if
bacteriological response to the study drug was not
evaluable for any reason). In addition, a superinfection
was defined as the appearance of a new organism in a
patient who was symptomatic. For patients with an end of
therapy response of eradication or presumed eradication,
test-of-cure bacteriologic eradication was defined as:
continued eradication, presumed continued eradication,
eradication with relapse (original causative organism absent
at end of therapy, but reisolated at test-of-cure), eradication
with reinfection (original organism eradicated, but new
causative organism identified) and indeterminate (not
evaluable for any reason).
Safety
All patients receiving at least one dose of study drug were
evaluable for safety (intent-to-treat population). Safety was
evaluated on the basis of physical examination findings,
ECGs, adverse events, intercurrent illness and laboratory
tests, including routine hematology, blood chemistry and
urinalysis tests. Investigators rated each adverse event
subjectively according to relationship to study drug
(probable, possible, remote, or none) and severity (mild,
moderate, severe, or serious or life-threatening).
EFFICACY ANALYSES
Three populations of patients were analysed for ecacy in
this study: patients considered valid for clinical ecacy
(defined below), those considered microbiologically valid
(i.e. patient valid for clinical ecacy with a causative
bacteria isolated and identified within 48 h before onset of
therapy), and patients valid for safety (i.e. any patient who
has received at least one dose of study drug).
For a course of therapy to be judged valid for clinical
ecacy, the following criteria were mandated: AECB
confirmed both by appropriate history of underlying
disease and presentation with symptoms of acute infection;
all inclusion/exclusion criteria met; study drug given for at
least 48 h if a clinical failure, or for at least 4 days if a
clinical success; no concurrent administration of non-study
antimicrobial agents, unless the patient was a treatment
failure or had recurring infection; and at least 80%
compliance with study drug regimen.
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The primary objective of the study was to determine if 5-
day moxifloxacin was equivalent to 5-day azithromycin
therapy, in terms of the rate of clinical resolution at the test-
of-cure visit. Bacteriologic response was a secondary
objective. Using the normal approximation to the binomial
distribution, true clinical failure rates of 10% in both
treatment groups, a lower limit of equivalence of 10% for
the difference between treatments, and a one-sided alpha of
0?025, the 221 valid patients in the moxifloxacin group and
the 243 valid patients in the azithromycin group provided
95% power to reject the null hypothesis of inequivalence.
Power would be higher for the analysis using Mantel–
Haenszel weights.
For categorical demographic and baseline medical
characteristics, a chi-squared test was used to test for the
differences between the two treatment groups. For con-
tinuous variables, a one-way analysis of variance was used,
with a term included for treatment.
For each evaluation of clinical and bacteriologic re-
sponse, a two-sided 95% confidence interval (CI) for the
weighted difference between treatment groups was con-
structed using Mantel–Haenszel weights (weighting by
center). Equivalence was defined as the lower limit of the
two-sided 95% CI for the difference between groups being
greater than 710%.
A comparison of the timecourse of bacteriologic eradica-
tion between treatment groups was also evaluated at one
site. The presence of causative bacteria was assessed once
per day during therapy in each patient and the data
analysed using exact contingency table methods.
Comparisons of the incidence rates of adverse events
between the two study drug groups were done descriptively.
Events were tabulated by type (according to the COSTART
glossary) and frequency for all adverse events and for those
events considered to be related to drug treatment.TABLE 1. Demographics and baseline medical characteristics: cl
Variable
Age, years
Mean+SD
Range
Sex, n (%) male
Race, n (%) Caucasian
Type of AECB infection as per Anthonisen (8), n (%)
I
II
III
Mean number of exacerbations in past 12 months
History of cigarette smoking, past or present, n (%)
Current cigarette smoker, n (%)
Mean length of history (years)
Mean number cigarettes smoked per day
*Includes patients who had pretherapy pathogen.Results
STUDY POPULATION
Five hundred and sixty-seven adults with AECB were
enrolled at 37 clinical sites and comprised the safety (intent-
to-treat) population (283 moxifloxacin, 284 azithromycin).
The clinically-valid population included 464 patients (221
moxifloxacin, 243 azithromycin), of which 237 (119
moxifloxacin, 118 azithromycin) patients made up the
microbiologically-valid group. One hundred and three
patients were excluded from the clinical ecacy-valid
analysis (62 moxifloxacin, 41 azithromycin). Reasons for
exclusion included: essential data missing or invalid
(n=69), entry criteria violations (n=13), inadequate dura-
tion of treatment (n=11), use of prohibited pre- or post-
therapy medications (n=7) and lost-to-follow-up (n=3).
The primary reasons for disqualification were similar
between the two study drug groups.
The baseline demographics and medical characteristics of
the clinically-valid ecacy patient population were similar
between the two treatment groups (Table 1). There were no
statistically significant differences between treatment
groups with respect to age, sex, or race. Over 75% of
patients in both treatment groups were active cigarette
smokers. The majority of patients in each treatment group
had type 1 severity of infection (470%) (Table 1). A mean
of 2?2 AECB episodes were reported during the past 12
months for both study drug groups combined. Baseline
demographic and medical characteristics in the safety and
microbiologically-valid groups were similar to those in the
clinically-valid population.
Clinical signs and symptoms present at study entry for
the clinically ecacy-valid patients revealed that greater
than half of moxifloxacin- and azithromycin-treated
patients had greatly increased cough frequency, sputum
production and sputum thickness, as well as evidence ofinically-valid population
Moxifloxacin
(N=221)
Azithromycin
(N=243)
53?9+14?5 54?5+15?7
19–88 20–86
120 (54) 135 (56)
142 (64) 163 (67)
171 (77) 178 (73)
47 (21) 63 (26)
3 (1) 2 (51)
2?3 2?2
188 (85) 190 (78)
117 (53) 119 (49)
30?1 31?6
25?9 26?1
FIG. 1. Eradication/presumed eradication rates for
microbiologically-valid population. moxifloxaxin;
zithromycin.
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approximately one-third of moxifloxacin- and azithromy-
cin-treated patients had greatly increased dyspnea,
decreased breath sounds, and prolongation of their
expiratory phase compared to their pre-exacerbation base-
line condition.
TREATMENT EFFICACY
Clinical response
For the clinically ecacy-valid population, clinical cure at
the end of therapy (0–6 days post-therapy) was reported in
90% of moxifloxacin- and 92% of azithromycin-treated
patients (Table 2). At the test-of-cure evaluation, 88% of
patients in each group were clinically cured (Table 2).
Recurrence was reported for seven moxifloxacin- and 10
azithromycin-treated patients. Altogether, 27 moxifloxacin-
and 29 azithromycin-treated patients were categorized as
clinical failures at test-of-cure. Among the 27 moxifloxacin
treatment failures, four patients achieved bacteriologic
eradication and 10 had presumed or documented persis-
tence. For the 29 azithromycin failures, three had eradica-
tion, two had eradication with recurrence and 11 were
presumed or known persisters. The remainder of clinical
failures in both treatment groups did not have valid
bacteriological responses due to the absence of an identifi-
able pathogen pretherapy. Exploratory analyses failed to
reveal any clinically significant differences in response rates
based on demographic or baseline medical characteristics
(data not shown).
Statistical equivalence between the moxifloxacin and
azithromycin 5-day treatment regimens was also established
for clinical ecacy in the intent-to-treat population (Table 2).
Bacteriologic Response
Among 567 patients enrolled, 280 (49%) patients had at
least one pretherapy organism isolated and identified prior
to initiation of study drug therapy. Of these 280 patients,
237 patients were also valid for ecacy and were said to be
microbiologically-valid, from which a total of 259 causative
bacteria (133 moxifloxacin, 126 azithromycin) were isolated
and identified. Fifteen patients in the moxifloxacin group
and six patients in the azithromycn group each had twoTABLE 2. Clinical cure rates
Clinically-valid
Moxifloxacin
n=N (%)
Azithromycin
n=N (%)
M
End of therapy
(0–6 days post-therapy)
192/212 (91) 208/227 (92) 1
Test-of-cure
(14–21 days post-therapy)
194/221 (88) 214/243 (88) 1causative organisms isolated and identified; one additional
azithromycin patient had three organisms identified at
enrollment. The most commonly isolated organisms in the
microbiologically-valid group were H. influenzae [71
(27%)], M. catarrhalis [49 (19%)], S. pneumoniae [39
(15%)], and H. parainfluenzae [29 (11%)]. While none of
the pretherapy isolates were resistant to moxifloxacin, 36
isolates were resistant to azithromycin. Of the common
respiratory pathogens, 13 H. influenzae isolates were
azithromycin-resistant, six isolates of S. pneumoniae were
azithromycin-resistant, and nine H. parainfluenzae isolates
were azithromycin-resistant.
Analyses for bacteriologic response at the end of therapy,
including presumed eradication, also revealed similar
response rates between the study drug regimens (96%
moxifloxacin and 94% azithromycin; Fig. 1). At the end of
therapy, five bacteria in the moxifloxacin group were found
to be persistent or presumed persistent, including two
Pseudomonas spp., two Stenotrophomonas maltophilia, and
one Alcaligenes sp. Azithromycin, on the other hand, failed
to eradicate seven of the more common respiratoryMicrobiologically-valid Safety
oxifloxacin
n=N (%)
Azithromycin
n=N (%)
Moxifloxacin
n=N (%)
Azithromycin
n=N (%)
06/116 (91) 104/115 (90) 228/252 (90) 239/261(92)
05/119 (88) 102/118 (86) 203/237 (86) 218/250 (87)
TABLE 3. Eradication rates for the most commonly isolated pretreatment organisms
End of therapy Test-of-cure
Moxifloxacin
n=N (%)
Azithromycin
n=N (%)
Moxifloxacin
n=N (%)
Azithromycin
n=N (%)
Haemophilus influenzae 34/34 (100) 33/36 (92) 34/35 (97) 30/36 (83)
Moraxella catarrhalis 29/29 (100) 20/20 (100) 29/29 (100) 20/20 (100)
Haemophilus parainfluenzae 16/16 (100) 10/13 (77) 14/16 (88) 8/13 (62)
Streptococcus pneumoniae 17/17 (100) 19/19 (100) 16/18 (89) 18/21 (86)
Staphylococcus aureus 8/8 (100) 7/7 (100) 8/8 (100) 7/7 (100)
TABLE 4. Drug-related adverse events occurring in at least
2% of patients
Adverse event Moxifloxacin n (%)
N=283
Azithromycin n (%)
N=284
Abdominal pain 5 (2) 7 (2)
Headache 6 (2) 5 (2)
Asthenia 5 (2) 1 (51%)
Nausea 15 (5) 9 (3)
Diarrhea 13 (5) 19 (7)
Dry mouth 5 (2) 4 (1)
Dizziness 9 (3) 3 (1)
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fluenzae and one P. aeruginosa. The eradication rates at the
end of therapy for the most commonly isolated pretherapy
bacteria may be found in Table 3. For these key respiratory
pathogens moxifloxacin eradicated 100% of organisms
compared to 77–100% eradication following azithromycin
therapy. Superinfections were reported for three moxiflox-
acin-treated patients and were due to one each of Serratia
marcescens, Alcaligenes sp. and H. influenzae, whereas twice
as many azithromycin-treated patients experienced a super-
infection (Staphylococcus aureus62, S. pneumoniae62 and
one each of Pseudomonas sp., H. influenzae and H.
parainfluenzae).
At the test-of-cure evaluation, continued and/or pre-
sumed eradication was reported in 89% of moxifloxacin-
and 86% of azithromycin-treated patients (95%
CI=76?14, 11?24). A recurring infection was experienced
by one moxifloxacin (Klebsiella pneumoniae) and two
azithromycin patients (H. influenzae, H. parainfluenzae). A
reinfection was reported for one moxifloxacin patient
(Cedecea apagei) and five azithromycin patients (two H.
influenzae and one each of K. pneumoniae, P. aeruginosa
and H. parahemolyticus). The eradication rates at the test-
of-cure visit for the most commonly isolated pretherapy
bacteria are outlined in Table 3. Eradication rates were
similar except for Haemophilus spp., wherein moxifloxacin
eradicated 94% of all organisms compared to 78% in
azithromycin-treated patients.Time-course to bacteriological eradication
Data were collected only for microbiologically-valid
patients from a single center. Eradication of the original
causative organism was achieved by day 3 in 17 of 27 (63%)
moxifloxacin- and 13 of 27 (48%) azithromycin-treated
patients (P=0?11). One additional patient in each treat-
ment group achieved bacteriologic eradication by day 4.
Two additional patients given azithromycin had their
pretherapy pathogen eradicated by day 5. In addition, nine
patients from the moxifloxacin group and seven patients in
the azithromycin group achieved eradication for the first
time at end of therapy. None of the moxifloxacin-treated
patients but four patients in the azithromycin group had
persistent infections at end of therapy.
SAFETY AND ADVERSE EVENTS
One hundred and sixteen (41%) moxifloxacin- and 108
(38%) azithromycin-treated patients reported at least one
treatment-emergent adverse event. Of these, drug-related
adverse events, as assessed by the investigator, were
reported in 61 (22%) moxifloxacin and 49 (17%) azithro-
mycin patients. The rates of specific drug-related events
were reported in similar frequencies with diarrhea and
nausea being the two most common events reported for
both groups. The most common drug-related events
(42%) for both treatment groups are summarized in
Table 4.
Of the adverse events reported, most were categorized as
mild/moderate (90% moxifloxacin, 94% azithromycin) and
improved or resolved without intervention. Study drug was
prematurely discontinued due to one or more adverse
events in six moxifloxacin-treated patients (no one event
predominated). Five of these six discontinuations were
considered to be possibly/probably-related to study
drug (e.g., facial numbness, headache, lightheadedness,
dizziness, anxiety, nausea, vomiting). The sixth patient was
discontinued because of severe asthma unrelated to the
study drug. There was one death in this study, unrelated to
study treatment, in the azithromycin group, due to a
cerebrovascular accident that was preceded by a myocardial
infarction.
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nine in the moxifloxacin group and seven in the azithro-
mycin group (including the death). These events included:
asthma, gastroenteritis, anxiety, carcinoma, pancytopenia,
sepsis, fever, pneumonia, bronchitis, myocardial infaction.
Only the asthma exacerbation resulted in study drug
discontinuation but was not considered to be related to
study drug treatment.
Discussion
Identification of the bacterial etiology of lower respiratory
infection and knowledge of antimicrobial susceptibility is
the ideal approach to selecting antimicrobial treatment.
However, the advent of managed care has limited the
physician’s ability to isolate and identify the common
respiratory tract organisms that infect the AECB patient
residing in the community because culture and suscept-
ibility testing are no longer routinely permitted. While re-
evaluation of this practice is necessary, empirical antimi-
crobial therapy that is safe and effective for the anticipated
pathogens, with consideration of local resistance patterns,
must be prescribed. Selection of the appropriate antimicro-
bial has recently become more challenging with the
increasing incidence of beta-lactam and macrolide-resistant
S. pneumoniae and beta-lactamase-producing H. influenzae
(10–15).
Our study was designed to establish the effectiveness of 5-
day moxifloxacin compared to 5-day azithromycin in
patients with AECB, including those with a proven
bacterial etiology. Patients were carefully evaluated and
stratified based on severity of illness. Because antimicrobial
therapy has been shown to be of benefit for the sicker
patients (8), predominately patients with type I AECB were
enrolled. We found that clinical response at the test-of-cure
visit was 88% for both the 5-day moxifloxacin-treated
patients and the patients given azithromycin for 5 days.
Similar clinical cure rates were observed for those patients
with a confirmed infectious etiology (88% vs. 86%,
respectively). Amongst those considered clinically-valid,
moxifloxacin therapy was associated with fewer super-
infections and reinfections when compared to those given
azithromycin. Although bacteriologic eradication rates for
individual organisms were similar for both treatment
groups, at the end of therapy visit moxifloxacin eradicated
100% of the five most common pathogens (H. influenzae,
M. catarrhalis, H. parainfluenzae, S. pneumoniae, S. aureus),
whereas eradication following azithromycin ranged from
77% to 100%. A potentially important clinical difference in
eradication rates was seen at the test-of cure visit where
22% of azithromycin patients had a persistent Haemophilus
spp. pathogen compared to only 6% persistence in
moxifloxacin-treated patients.
This study corroborates several earlier investigations
which demonstrate that moxifloxacin is an effective agent
for the management of patients with AECB (19–21). A
recent study by Chodosh et al. compared the ecacy and
safety of moxifloxacin to clarithromycin for the treatment
of4900 patients with bacterial proven AECB (19). Clinicalresolution was reported in 89% of 5-day moxifloxacin-,
91% of 10-day moxifloxacin-, and 91% of clarithromycin-
treated patients. Corresponding bacteriologic eradication
rates were 89% for 5-day moxifloxacin, 91% for 10-day
moxifloxacin, and 85% for the clarithromycin group. For
S. pneumoniae, in particular, 5-day and 10-day moxiflox-
acin regimens eradicated 100% and 95% of organisms,
respectively, compared to 91% in the clarithromycin group.
Wilson et al. compared the ecacy and safety of
moxifloxacin to clarithromycin among 745 patients with
AECB (20). Of importance, resistance of pretherapy
organisms was only reported for clarithromycin, with
15% of all isolates being clarithromycin-resistant. Although
clinical cure rates were similar between moxifloxacin and
clarithromycin (*88% each), moxifloxacin was associated
with a statistically higher bacteriologic eradication rate
(77% vs. 62%, respectively).
A recent meta-analysis of 42000 patients with AECB
who received treatment with either moxifloxacin or a
comparator agent (clarithromycin or cefuroxime axetil)
found that moxifloxacin had higher end of therapy clinical
and bacteriologic success rates (each 95%) vs. the
comparator group (85% to 92%) (21). Specifically,
bacteriologic eradication rates for the comparator anti-
microbials against S. pneumoniae (92% clarithromycin,
90% cefuroxime axetil) and H. influenzae (72% clarithro-
mycin, 88% cefuroxime axetil) were lower compared to
moxifloxacin (496%).
Although the standard duration of antimicrobial therapy
for AECB of bacterial origin has ranged from 10 to 14 days,
the optimal length of therapy is still being defined (4).
Several studies, some including fluoroquinolones, have
evaluated shorter course regimens (3–10 days) with reason-
able success rates (19,22–25). The Chodosh study described
above was pivotal in suggesting that 5-day moxifloxacin
was effective for ABECB (19). Our data also confirm that 5-
day moxifloxacin therapy is effective for the treatment of
ABECB.
Because morbidity can be extremely high in patients with
AECB, the time to improvement is important when
considering antimicrobial options. In our analysis of the
rate of bacteriologic eradication among a single center
subset of our patient population, we found that 63% of
moxifloxacin-treated patients showed eradication of their
pathogen by day 3 of therapy compared to 48% of patients
in the azithromycin-treated group at the same time point.
Moreover, while none of the moxifloxacin-treated patients
had persistent organisms at the end of therapy, 15% (four
of 27) of the azithromycin-treated patients still had
evidence of bacteriologic persistence. The importance of
these findings requires further validation, and such studies
are now underway.
In the current trial, both moxifloxacin and azithromycin
were well-tolerated. We found that the most common
adverse events for both the 5-day moxifloxacin and
azithromycin regimen were gastrointestinal-related (e.g.
diarrhea). Very few patients discontinued study drug
prematurely due to an adverse event and the majority of
drug-related events were of mild to moderate intensity and
none required interventions.
1036 C. A. DEABATE ET AL.In summary, this trial has shown that patients with
AECB can be safely and effectively treated with 5 days of
moxifloxacin given once daily, without the need for a
loading dose, compared to the typical 5-day regimen of
azithromycin, which includes a loading dose. In addition,
moxifloxacin can be administered with or without food
without compromising the quinolone’s pharmacodynamic
properties and potential effectiveness. A short-course regi-
men of moxifloxacin is therefore an effective treatment
option for patients with ABECB.
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